Galecto Inc. (GLTO): Price and Financial Metrics


Galecto Inc. (GLTO): $2.30

0.06 (+2.68%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add GLTO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

GLTO Stock Price Chart Interactive Chart >

Price chart for GLTO

GLTO Price/Volume Stats

Current price $2.30 52-week high $2.80
Prev. close $2.24 52-week low $1.04
Day low $2.08 Volume 85,667
Day high $2.40 Avg. volume 68,765
50-day MA $1.59 Dividend yield N/A
200-day MA $1.81 Market Cap 58.84M

Galecto Inc. (GLTO) Company Bio


Galecto, Inc. operates as a clinical-stage biotechnology company developing therapeutics which are designed to target the biological processes to treat fibrotic and related diseases including cancer. Its product portfolio includes GB0139, GB1211, GB2064, and GB1211. The company was founded by Ulf Nilsson, Hakon Leffler, Tariq Sethi, and Hans T. Schambye in 2011 and is headquartered in Copenhagen, Denmark.


GLTO Latest News Stream


Event/Time News Detail
Loading, please wait...

GLTO Latest Social Stream


Loading social stream, please wait...

View Full GLTO Social Stream

Latest GLTO News From Around the Web

Below are the latest news stories about GALECTO INC that investors may wish to consider to help them evaluate GLTO as an investment opportunity.

Is Galecto (NASDAQ:GLTO) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | December 11, 2022

Galecto Announces Upcoming Poster Presentation Detailing Results from the Intermediate Assessment of the MYLOX-1 Trial at the 2022 American Society of Hematology (ASH) Annual Meeting

Intermediate assessment of GB2064 in the Phase 2 myelofibrosis trial showed target engagement in the bone marrow and reduction in collagen fibrosis in four out of five evaluable patients GB2064 is an oral inhibitor of the collagen cross-linking enzyme LOXL-2, which is linked to myelofibrosis BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibros

Yahoo | December 7, 2022

Galecto, Inc. (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Galecto, Inc. (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Yahoo | November 24, 2022

All You Need to Know About Galecto, Inc. (GLTO) Rating Upgrade to Strong Buy

Galecto, Inc. (GLTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Yahoo | November 11, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

We're starting off the day with a look at the biggest pre-market stock movers traders need to know about on Tuesday morning!

William White on InvestorPlace | November 8, 2022

Read More 'GLTO' Stories Here

GLTO Price Returns

1-mo 100.00%
3-mo 17.95%
6-mo 20.42%
1-year -4.17%
3-year N/A
5-year N/A
YTD 100.00%
2022 -62.05%
2021 -75.78%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 3.9014 seconds.